Biotech Values

[mcbio]

AAVL

In other words, if the stocks sells off despite fairly good data, it could become a good buy. Yes, I agree with that :- )

LOL Bingo. Never know for sure though what expectations exactly the market is pricing in.

The other thing that I think could bode well for AAVL is the OPHT hypothesis that injecting their PDGF drug before VEGF (or is it other way around?) may produce better data than doing both at same time. If this pans out, then there is less concern over competing PDGF/VEGF drugs that are being co-formulated. Gives AAVL drug more room to operate presumably.